A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 45 years of age
Established cardiovascular disease A stable coronary disease B cerebrovascular disease C peripheral artery disease
Without established coronary disease D pharmacologically treated type 2 diabetes mellitus and one or more risk factor(s) for cardiovascular disease E 3 or more risk factors for cardiovascular disease
Receiving evidence-based medical and dietary management of dyslipidemia
You may not be if
Occurrence of myocardial infarction, hospitalization for unstable angina, stroke or revascularization (coronary, carotid or peripheral) within three months prior to randomization
Uncontrolled hypertension
Uncontrolled diabetes
Concomitant treatment with any other drug raising HDL-C
Previous treatment with compounds targeting cholesteryl ester transfer protein (CETP)
